Skip to main content
Premium Trial:

Request an Annual Quote

See, You Can Go from Industry to Academia

Marc Tessier-Lavigne, the executive vice president for research and the chief scientific officer at Genentech, is leaving the company to take the helm of Rockefeller University in New York, reports the New York Times. Tessier-Lavigne will take up the position in March, succeeding Paul Nurse, who is returning to the UK to lead the Royal Society there. The Times notes that Tessier-Lavigne is the "first departure from the company’s top scientific ranks since its acquisition by Roche in March 2009," but adds that Tessier-Lavigne's departure is not related to the Roche-Genentech merger. "I wasn't looking to move away. In fact, this is probably the only job that could have lured me away from Genentech," he says. Tessier-Lavigne will also be the first Rockefeller president to come from industry, the Times adds.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.